Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Special report: companion diagnostics--example of BRAF gene mutation testing to select patients with melanoma for treatment with BRAF kinase inhibitors.

[No authors listed]

Technol Eval Cent Assess Program Exec Summ. 2011 Nov;26(7):1-5. No abstract available.

PMID:
22724160
2.

[BRAF mutation testing for the choice of melanoma treatment].

Imianitov EN.

Arkh Patol. 2012 Sep-Oct;74(5):65-71. Review. Russian.

PMID:
23342664
3.

Biological challenges of BRAF inhibitor therapy.

Puzanov I, Burnett P, Flaherty KT.

Mol Oncol. 2011 Apr;5(2):116-23. doi: 10.1016/j.molonc.2011.01.005. Epub 2011 Feb 16. Review.

4.

Oncogenetics of melanoma: basis for molecular diagnostics and therapy.

Held L, Eigentler TK, Meier F, Held M, Röcken M, Garbe C, Bauer J.

J Dtsch Dermatol Ges. 2011 Jul;9(7):510-6. doi: 10.1111/j.1610-0387.2011.07603.x. Epub 2011 Jan 19. Review. English, German.

PMID:
21244632
5.

Therapeutic targets in melanoma: map kinase pathway.

Haluska FG, Ibrahim N.

Curr Oncol Rep. 2006 Sep;8(5):400-5. Review.

PMID:
16901402
6.

From targeted monotherapy to combined BRAF-MEK inhibitors and integrated genome analysis for melanoma treatment.

Roukos DH, Papaloukas C, Tzaphlidou M.

Future Oncol. 2013 Jan;9(1):5-8. doi: 10.2217/fon.12.169. No abstract available.

PMID:
23252557
7.

Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?

Passeron T, Lacour JP, Allegra M, Ségalen C, Deville A, Thyss A, Giacchero D, Ortonne JP, Bertolotto C, Ballotti R, Bahadoran P.

Exp Dermatol. 2011 Dec;20(12):1030-2. doi: 10.1111/j.1600-0625.2011.01385.x.

PMID:
22092579
8.

BRAF inhibitors and melanoma.

Flaherty KT.

Cancer J. 2011 Nov-Dec;17(6):505-11. doi: 10.1097/PPO.0b013e31823e5357. Review.

PMID:
22157295
9.

Effectively targeting BRAF in melanoma: a formidable challenge.

Fecher LA, Amaravadi R, Schuchter LM.

Pigment Cell Melanoma Res. 2008 Aug;21(4):410-1. doi: 10.1111/j.1755-148X.2008.00485.x. No abstract available.

PMID:
18710372
10.

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF.

J Clin Oncol. 2011 Apr 1;29(10):1239-46. doi: 10.1200/JCO.2010.32.4327. Epub 2011 Feb 22.

PMID:
21343559
11.

Special report: multiple molecular testing of cancers to identify targeted therapies.

BlueCross BlueShield Association..

Technol Eval Cent Assess Program Exec Summ. 2013 Jun;28(1):1-2. No abstract available.

PMID:
23865106
12.

Challenges ahead for companion diagnostics.

Schmidt C.

J Natl Cancer Inst. 2012 Jan 4;104(1):14-5. doi: 10.1093/jnci/djr535. Epub 2011 Dec 14. No abstract available.

PMID:
22173588
13.

Implementation of a companion diagnostic in the clinical laboratory: the BRAF example in melanoma.

Mancini I, Pinzani P, Simi L, Brandslund I, Vermeersch P, Di Resta C, Schwab M, Marc J, van Schaik R, Pazzagli M; European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)–European Society of Pharmacogenomics and Theranostics (ESPT) joint Working Group Personalized Laboratory Medicine (WG-PLM)..

Clin Chim Acta. 2015 Jan 15;439:128-36. doi: 10.1016/j.cca.2014.10.020. Epub 2014 Oct 23.

PMID:
25454717
14.

BRAF, a target in melanoma: implications for solid tumor drug development.

Flaherty KT, McArthur G.

Cancer. 2010 Nov 1;116(21):4902-13. doi: 10.1002/cncr.25261. Review.

15.

Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report.

Sondak VK, Smalley K.

Pigment Cell Melanoma Res. 2009 Aug;22(4):386-7. doi: 10.1111/j.1755-148X.2009.00593.x. No abstract available.

PMID:
19624312
16.

The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?

Nissan MH, Solit DB.

Curr Oncol Rep. 2011 Dec;13(6):479-87. doi: 10.1007/s11912-011-0198-4. Review.

PMID:
21997758
17.

Advances in drug development. BRAF validation in melanoma.

Flaherty K.

Clin Adv Hematol Oncol. 2010 Jan;8(1):31-4. No abstract available.

PMID:
20351680
18.

BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance.

Alcalá AM, Flaherty KT.

Clin Cancer Res. 2012 Jan 1;18(1):33-9. doi: 10.1158/1078-0432.CCR-11-0997.

19.

Special report: vaccines for the treatment of malignant melanoma.

[No authors listed]

Tecnologica MAP Suppl. 2001 Apr 13:19-20.

PMID:
11718143
20.

Co-development of a companion diagnostic for targeted cancer therapy.

Cheng S, Koch WH, Wu L.

N Biotechnol. 2012 Sep 15;29(6):682-8. doi: 10.1016/j.nbt.2012.02.002. Epub 2012 Feb 25. Review.

PMID:
22391147

Supplemental Content

Support Center